Dicerna Pharmaceuticals’ (DRNA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) in a research report released on Friday morning, MarketBeat reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $6.00.
DRNA has been the subject of several other reports. ValuEngine cut Dicerna Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, August 1st. Zacks Investment Research cut Dicerna Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, August 22nd. Finally, Chardan Capital reissued a hold rating on shares of Dicerna Pharmaceuticals in a research note on Monday, August 14th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $6.81.
Dicerna Pharmaceuticals (NASDAQ:DRNA) traded up $0.19 during mid-day trading on Friday, hitting $7.97. The stock had a trading volume of 389,358 shares, compared to its average volume of 264,262.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). Dicerna Pharmaceuticals had a negative return on equity of 293.25% and a negative net margin of 5,895.26%. The company had revenue of $0.47 million for the quarter. During the same period last year, the firm earned ($0.68) earnings per share. Dicerna Pharmaceuticals’s quarterly revenue was up 192.6% compared to the same quarter last year. research analysts forecast that Dicerna Pharmaceuticals will post -3.13 earnings per share for the current fiscal year.
Several large investors have recently added to or reduced their stakes in DRNA. EcoR1 Capital LLC boosted its position in shares of Dicerna Pharmaceuticals by 101.0% during the 2nd quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after acquiring an additional 385,992 shares in the last quarter. Deschutes Portfolio Strategy LLC acquired a new position in shares of Dicerna Pharmaceuticals during the 3rd quarter worth about $575,000. Paloma Partners Management Co boosted its position in shares of Dicerna Pharmaceuticals by 49.7% during the 1st quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after acquiring an additional 53,131 shares in the last quarter. Bourgeon Capital Management LLC boosted its position in shares of Dicerna Pharmaceuticals by 188.9% during the 2nd quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after acquiring an additional 25,500 shares in the last quarter. Finally, Birchview Capital LP boosted its position in shares of Dicerna Pharmaceuticals by 125.0% during the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 25,000 shares in the last quarter. 55.91% of the stock is owned by institutional investors and hedge funds.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.